EGFR and non-small cell lung carcinoma: The HERTHENA-Lung01 trial [82] was a phase II study evaluating patritumab deruxetecan as a third-line therapy in 225 patients with EGFR mutation-positive metastatic or locally advanced NSCLC whose disease had progressed after EGFR-TKI plus platinum-based combination therapy.